Thematic meeting: New antiviral strategies: From Bench to Bedside
The COVID-19 epidemic of recent years has taught us that a multidisciplinary approach to scientific research is essential for the development of new therapies. The « New antiviral strategies : from bench to bedside» Thematic meeting is at the frontiers of developing new health technologies for the benefit of patients. It will be an opportunity for international experts from two different disciplines, chemistry and biology, to exchange. Also young researchers (PhD students, post-docs..) will be able to present their research work and expand their networks.
- deadline 31st Mar. for registration.
- deadline 20th Mar. for poster abstract submission.
Any queries ? Contact : firstname.lastname@example.org
Date & Location
- Wednesday, 19th Apr. 2023. 9 am - 5:30 pm
- Amphitheater Duclaux, Institut Pasteur, 28 Rue du Docteur Roux, 75015 Paris, France.
- 9h15 Welcome coffee
- 10h Welcome address
Noël Tordo (SFV, Institut Pasteur) & Jean-Yves Ortholand (SCT, Edelris)
- 10h10-10h40 Opening keynote lecture
Antivirals, a lot has been achieved, yet a long way to go.
Johan Neyts (KU Leuven, BE)
Session 1 -The host as a target
- 10h40 Immunity
Protective antibodies targeting hantavirus glycoproteins
Pablo Guardado Calvo (Institut Pasteur, FR)
Activating immune pathways to curechronic hepatitis B:From the bench to the clinic
Antoine Alam (Evotec ID, FR)
- 11h20 Vaccins and new technologies
Title to be communicated
Odile Launay (Centre de vaccinologie de Cochin, FR)
Messenger RNA-based modalities as alternatives to conventional approaches to fight infectious diseases
Chantal Pichon (CBM, Orleans, FR)
- 12h00 Epitranscriptome
Viral and cellular epitranscriptomics: New players in RNA virus infections.
Patrick Eldin (CNRS Montpellier, FR)
Nucleosides and Oligonucleotides as inhibitors of viral RNA methylation by methyltransferases
Françoise Debart (CNRS Montpellier, FR)
- 12h40 Lunch break and Poster session
Session 2 -Virus as targets
- 14h30 RNA virus and targets
Packaging of the influenza A virus genome: a suitable antiviral target?
Roland Marquet (IBMC Strasbourg, FR)
From fragment screening to inhibitors of the SARS-CoV-2 RNA genome
Julia Weigand (University of Marburg, DE)
- 15h10 DNA virus and targets
Preclinical research and development of nanoparticulated TRL2 agonist for the treatment of chronic HBV and HDV infections
David Durantel (CIRI, ENS Lyon, FR)
G-quadruplexes & Pathogens: targeting nucleic acid unusual structures
Jean-Louis Mergny (Ecole Polytechnique, FR)
- 15h50 Targeting the entry
Screening antibodies and other molecules against SARS-CoV-2 and Mpox virus
Olivier Schwartz (Institut Pasteur, FR)
Phenotypic screening: an indirect approach for the discovery of molecules impacting intracellular trafficking
Jean-Christophe Cintrat (CEA; IdF,FR)
- 16h30 Emergence, identification and detection
The Preclinical Study Group (GEPC) of the ANRS-MIE
Xavier de Lamballerie (Université de Marseille, FR)
From the screening of the Curie-CNRS chemical library to the identification of an anti-HIV drug
Florence Mahuteau-Betzer (Institut Curie, Orsay)
- 17h10 Closing remarks
- 17h30 Cocktail